Development and validation of an individualized angiogenesis and tumor-infiltrating lymphocytes prognostic signature in nasopharyngeal carcinoma

• Published in: Pathology, research and practice research and practice, 2024-01, Vol.253, p.154936-154936, Article 154936
• Main Authors: Zhang, Ruyun, Liao, Xiaofei, Zhang, Bin, Huang, Xiaohong, Qin, Guanjie, Kong, Xiangyun, Xie, Yuan, Mo, Yunyan, Dai, Jinxuan, Gan, Chunqiao, Luo, Zan, Lu, Jingyan, Jiang, Wei
• Format: Article
• Language: English
• Subjects: Angiogenesis; Nasopharyngeal carcinoma; Prognosis，biomarker; Tumor-infiltrating lymphocytes
• ISSN: 0344-0338; 1618-0631
• DOI: 10.1016/j.prp.2023.154936

In recent years, targeted therapy and immunotherapy have become ideal choices for the treatment of advanced, metastatic, recurrent, and drug-resistant nasopharyngeal carcinoma (NPC), but the lack of understanding of the relationship and mechanism between TILs and angiogenic factors hinders therapeutic development and optimization. In this study, the expression of angiogenesis-related markers (VEGF-A,VEGFR-2) and TILs (CD4+T,CD8+T) was studied by using immunohistochemistry (IHC). Then we constructed an immunohistochemical scoring model for the co-expression of angiogenesis-related markers and TILs (COV+TIL score)in the training (n = 124) and validated the accuracy and reliability of the scoring system in the validation cohorts (n = 114), respectively We established the COV+TIL score model and stratified patients into different risk level in the training cohorts according to COV+TIL score (cut-off value=28). Patients in the high-risk group had worse prognosis in the training cohorts five-year overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRRFS), and distant metastasis-free survival (DMFS) was lower than that of patients in the low-risk group, and this result was validated in the validation cohorts ( 5-year OS in the high-risk and the low-risk group 46.8% vs. 83.4%, HR: 3.42, 95%CI: 1.77–6.61, p